[Past and future of allergen immunotherapy].
Specific immunotherapy involves the administration of allergen extracts to achieve clinical tolerance of the allergens which cause symptoms in patients with allergic conditions. Immunotherapy has been shown to be effective in patients with mild forms of allergic diseases, specially in upper airway diseases. Recent studies suggest that specific immunotherapy may also modify the course of allergic disease, by reducing the risk of developing new allergic sensitizations, and also inhibiting the development of clinical asthma in children treated for allergic rhinitis. The traditional subcutaneous route is burdened with the risk of severe adverse events, therefore, local routes have been investigated and developed. The sublingual route is supported by numerous controlled trials showing its efficacy in rhinitis. The safety profile, assessed in clinical trials studies, is satisfactory. Several points still need to be elucidated, including mechanisms of action, optimal dosage, cost-effectiveness, and adherence. New approaches using mimic bacterial DNA vaccines alone or associated to modified allergen, which enhances immunogenicity in terms of eliciting a Th1-type response vaccines, are also undergoing serious consideration.
Service de pédiatrie orientée en pneumologie et en allergologie, hôpital d'enfants Armrand-Trousseau, AP-HP, 26, avenue du Docteur-Arnold-Netter, 75571 Paris cedex 12, France. jocelyne.just@trs.ap-hop-paris.fr <jocelyne.just@trs.ap-hop-paris.fr>
J
J
Just
E
E
Goudard
A
A
Grimfeld
D000286:Administration, Sublingual; D001249:Asthma / Q000276:immunology* / Q000628:therapy*; D003888:Desensitization, Immunologic; D006801:Humans; D007279:Injections, Subcutaneous / Q000009:adverse effects; D012220:Rhinitis / Q000276:immunology* / Q000628:therapy*; D019444:Vaccines, DNA / Q000008:administration & dosage
D019444:Vaccines, DNA